pathway that is not intended for evaluating safety and effective ness. This pathway, called the 510(k) process, instead involves evaluation of "substantial equiva lence" to previously cleared de vices, many of which have never been assessed for safety and ef fectiveness and some of which are no longer in use because of poor clinical performance.
The Medical Device Amend ments of 1976 created three classes of devices: class I in cluded lowrisk devices, such as toothbrushes; class II contained moderaterisk devices, such as infusion pumps; and class III included highrisk devices and those awaiting proper classifica tion, such as metalonmetal hip implants. These classes roughly corresponded to the level of pre marketing review required. Thus, class I and II devices underwent review for substantial equiva lence to devices already on the market, also called preamend ment devices (although subse quent legislation granted ex emptions). Class III devices were meant to undergo the more rig orous premarket approval (PMA), the only pathway that re quires clinical data. However, class III devices were allowed to receive review for substantial equivalence temporarily, until the FDA downclassified these devices or promulgated regula tions requiring PMA. Congress had always intended class III de vices to undergo PMA, and in 1990, it directed the agency to establish a schedule to finish the transition to PMAs for all devices that were to remain in class III. 1 As of December 19, 2012, how ever, the FDA still had not com pleted this transition to PMA for highrisk devices, although it had stated its intention to clear pro posed rules for all remaining class III preamendment devices by December 31, 2012. 2 Current ly, 19 different types of class III devices, including metalonmetal hip implants, are allowed to reach patients through 510(k) clearance. Because of this loophole, compa nies that market these devices are often legally able to obtain clearance without demonstrating safety and effectiveness through clinical studies, but by claiming substantial equivalence to earlier "predicate devices" -or pieces of those devices -which may also have been found substantial ly equivalent to even earlier de vices, and so on, all the way back to preamendment devices. Be figure, and the interactive graphic, available with the full text of this article at NEJM.org).
The 510(k) clearance for the ASR XL focused on three charac teristics: the porous bone ingrowth surface, metalonmetal articula tion, and large femoral head sizes (57 to 63 mm), which were larger than those of the predicate total hip prostheses. These three char acteristics were uniquely combined in the ASR XL but were evaluated for "substantial equivalence" by comparing select characteristics to different predicate devices, none of which contained all of these characteristics (i.e., they were "split predicates").
The porous bone ingrowth sur face was not specific to the type of articulation; thus, in most cases, the predicates were not metalonmetal and were substan tially different in design from the ASR XL. None of the predicates in the ancestry had the same combination of characteristics as the ASR XL acetabular component.
Clearance of the large metal onmetal articulation was based on a much smaller group of pred icates, some of which differed substantially in design from the ASR XL or had poor clinical per formance. Ultimately, clearance was based on the claim that these predicate devices were sub stantially equivalent to three pros theses that were used before 1976: the McKee-Farrar, Ring, and Sivash metalonmetal total hip prostheses. It is important to note that these three devices were discontinued long ago (and well before clearance of the ASR XL) because their risk of revision was so much higher than that of other hip prostheses. 3, 4 One metalonmetal hip in use at the time of the application and whose use was well supported by clinical evidence was the original Metasul hip. However, this hip differed substantially in design from the ASR XL in two major ways. The cup was not solid metal, but instead consisted of a metal shell and a metal articular surface inlay with a polyethylene "sand wich" between the two. A second difference was head size: the Metasul had much smaller heads (≤32 mm) than the ASR XL.
The use of larger heads was an important characteristic of the ASR XL. The clearance for the large metal heads with sleeves was based in part on predicates that were not used in total hip replacement but were designed for use in partial hip replacement, in which the large metal heads articulate with the natural artic ular cartilage of the acetabulum, not with a metal cup.
This ancestry reveals serious flaws in the 510(k) procedure for metalonmetal hips, which re sulted in clearance of a new de vice that was never shown to be safe and effective. A clinical trial might have identified the high Each number represents a corresponding number in the Supplementary Appendix (available at NEJM.org), where the device names, companies, 510(k) numbers, and decision dates for most devices can be found.
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revision rate of the ASR, which became evident after 9 months when it was compared with all other total conventional hip pros theses in the Australian Joint Registry (9monthto1year haz ard ratio, adjusted for age and sex, 2.62 [95% confidence inter val, 1.67 to 4.11]) and which pre cipitously worsened over time. 5 As thousands of Americans are painfully learning, there are un known risks with devices that enter the market without clinical data showing safety and effective ness, and implanted body parts cannot be recalled as easily as defective auto parts. The recently passed Medical Device User Fee and Modernization Act contains a provision that should make it easier for the FDA to close the loophole for the remaining 19 class III devices by allowing the agency to reclassify devices by order rather than through regu lation. There would be value in an FDAsanctioned registry.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. T o promote successful recovery after a hospitalization, health care professionals often focus on issues related to the acute illness that precipitated the hospitaliza tion. Their disproportionate at tention to the hospitalization's cause, however, may be misdirect ed. Patients who were recently hospitalized are not only recover ing from their acute illness; they also experience a period of gen eralized risk for a range of ad verse health events. Thus, their condition may be better charac terized as a posthospital syn drome, an acquired, transient pe riod of vulnerability. This theory would suggest that the risks in the critical 30day period after discharge might derive as much from the allostatic and physio logical stress that patients expe rience in the hospital as they do from the lingering effects of the original acute illness. At the time of discharge, physiological sys tems are impaired, reserves are depleted, and the body cannot effectively defend against health threats.
Nearly one fifth of Medicare patients discharged from a hospi tal -approximately 2.6 million seniors -have an acute medical problem within the subsequent 30 days that necessitates another hospitalization. These recently dis charged patients have heightened risks of myriad conditions, many of which appear to have little in common with the initial diagno sis. For example, among patients admitted for treatment of heart failure, pneumonia, or chronic obstructive pulmonary disease (COPD), the cause of readmission is the same as that of the index admission for only 37%, 29%, and 36%, respectively. 1 The causes of readmission, regardless of the original admitting diagnosis, commonly include heart failure, pneumonia, COPD, infection, gas trointestinal conditions, mental illness, metabolic derangements, and trauma (see graph). The breadth of these readmission di agnoses has been shown in stud ies using administrative claims and those using chart reviews. Thus, this observation is not like ly to be merely the result of vari ation in coding. Further evidence of the distinctiveness of this syn drome is that information about the severity of the original acute illness predicts poorly which pa tients will have an adverse medi
